| Subject Of Report |
Type Of Client |
|
|
| Remuneration strategies for experts and opinion leaders acting as consultants to the pharmaceutical industry |
US Multinational Pharma |
| Obesity and non-insulin dependent diabetes mellitus & novel drug developments for NIDDM & insulin resistance |
French International Pharma |
| Development status of a respiratory drug |
Japanese Multinational |
| Identification and selection of CROs able to carry out three simultaneous studies in hyperphosphataemia in the USA |
Mid Sized UK Pharma |
| Phase I CROs in the UK with experience of recruiting or ability to recruit, healthy volunteers with CYP2D6 impaired activity |
Japanese Pharma |
| Capabilities of regulatory and statistical CROs (UK) |
Japanese Pharma |
| Selection of a strategic partner for development of a matrix metalloproteinase inhibitor |
European Multinational Pharma |
| Survey of opinion leaders and principal investigators in the field of immune system related diseases (Crohn's disease, lupus, rheumatoid arthritis) |
US Biotech company |
| Feasibility study of carrying out clinical trials in a neurological disease in Eastern Europe, and Latin America. |
US Biotech company |
| Feasibility study on CROs able to assist in the development of a schizophrenia drug |
German Multinational |
| Identification of CROs in Europe able to manage European regulatory affairs |
US Multinational |
| Identification of CROs in Europe able to conduct a phase I study in patients with renal impairment |
Japanese Pharma |
| Report on CROs with relevant clinical development experience in prostate cancer |
German Mid-Sized Pharma |
| Identification of CROs able to conduct a phase II study with patients with benign prostate hyperplasia and estimates of investigator fees per patient |
German Mid-SizedPharma |
| Identification of CROs able to conduct a phase II study with patients with confirmed detrusor instability |
German Mid-Sized Pharma |
| Recommendation of CROs able to undertake clinical trials with a developmental compound for the treatment of dermatitis |
Japanese Pharma |
| Capabilities of CROs in Eastern Europe, Australia, South Africa & South America |
US Biotech |
| CROs capable to carrying out development work with relation to a gene therapy compound |
UK Biotech |
| Report on European CROs able to undertake phase I studies in Japanese healthy volunteers |
Japanese Pharma |
| Survey of centralised outsourcing practice in large and medium pharma companies |
US Multinational Pharma |
